doi: 10.1161/hc5001.100624
(Circulation. 2001;104:3046.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S
From the Department of Medicine, Baylor College of Medicine, Houston, Tex (C.M.B.); the Department of Internal Medicine, Linköping University Hospital, Linköping, Sweden (A.G.O.); Merck Research Laboratories, Rahway, NJ (T.J.C., M.F.M.); and the Medical Clinic, Aker Hospital (T.R.P.), and Department of Medicine, Rikshospitalet (J.K.), Oslo, Norway.
Correspondence to Christie M. Ballantyne, MD, Baylor College of Medicine, 6565 Fannin, MS A-601, Houston, TX 77030. E-mail cmb{at}bcm.tmc.edu
Background— Patients with low HDL cholesterol (HDL-C) and elevated triglyceride had an increased risk for coronary heart disease (CHD) events and received the greatest benefit with fibrate therapy in substudy analyses of the Helsinki Heart Study and the Bezafibrate Infarction Prevention Study.
Methods and Results— In this post hoc analysis of the Scandinavian Simvastatin Survival Study, which enrolled patients with elevated LDL cholesterol (LDL-C) and CHD, subgroups defined by HDL-C and triglyceride quartiles were compared to examine the influence of HDL-C and triglyceride on CHD events and response to therapy. Patients in the lowest HDL-C (<1.00 mmol/L [39 mg/dL]) and highest triglyceride (>1.80 mmol/L [159 mg/dL]) quartiles (lipid triad; n=458) had increased proportions of other features of the metabolic syndrome (increased body mass index, hypertension, diabetes), men, prior myocardial infarction, prior revascularization, and ß-blocker use than patients in the highest HDL-C (>1.34 mmol/L [52 mg/dL]) and lowest triglyceride (<1.11 mmol/L [98 mg/dL]) quartiles (isolated LDL-C elevation; n=545). The major coronary event rate was highest in lipid triad patients on placebo (35.9%), and this subgroup had the greatest event reduction (relative risk 0.48, 95% CI 0.33 to 0.69); a significant treatment-by-subgroup interaction (P=0.03) indicated a greater treatment effect in the lipid triad subgroup than the isolated LDL-C elevation subgroup.
Conclusions— Patients with elevated LDL-C, low HDL-C, and elevated triglycerides were more likely than patients with isolated LDL-C elevation to have other characteristics of the metabolic syndrome, had increased risk for CHD events on placebo, and received greater benefit with simvastatin therapy.
Key Words: lipids • statins • trials
This article has been cited by other articles:
 |
|
 |
|
  G. Ferns and V. Keti HDL-cholesterol modulation and its impact on the management of cardiovascular risk Ann Clin Biochem, March 1, 2008; 45(2): 122 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Brighenti Dietary Fructans and Serum Triacylglycerols: A Meta-Analysis of Randomized Controlled Trials J. Nutr., November 1, 2007; 137(11): 2552S - 2556S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Criqui Triglycerides and Coronary Heart Disease Revisited (Again) Ann Intern Med, September 18, 2007; 147(6): 425 - 427. [Full Text] [PDF]
|
|
|
|
 |
|
 O. Ben-Yehuda High-Sensitivity C-Reactive Protein in Every Chart?: The Use of Biomarkers in Individual Patients J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2139 - 2141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Devaraj, E. Chan, and I. Jialal Direct Demonstration of an Antiinflammatory Effect of Simvastatin in Subjects with the Metabolic Syndrome J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4489 - 4496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bruckert Impact of lipid treatment on cardiovascular risk reduction: new therapeutic targets Eur. Heart J. Suppl., November 1, 2005; 7(suppl_L): L16 - L20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Grundy, J. I. Cleeman, S. R. Daniels, K. A. Donato, R. H. Eckel, B. A. Franklin, D. J. Gordon, R. M. Krauss, P. J. Savage, S. C. Smith Jr, et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation, October 25, 2005; 112(17): 2735 - 2752. [Full Text] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden 2nd International Symposium on Triglycerides and HDL: Metabolic syndrome Diabetes Care, October 1, 2005; 28(10): 2577 - 2584. [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Geluk, F. W. Asselbergs, H. L. Hillege, S. J.L. Bakker, P. E. de Jong, F. Zijlstra, and W. H. van Gilst Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial Eur. Heart J., July 1, 2005; 26(13): 1314 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Farnier, M. W. Freeman, G. Macdonell, I. Perevozskaya, M. J. Davies, Y. B. Mitchel, B. Gumbiner, and for the Ezetimibe Study Group Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia Eur. Heart J., May 1, 2005; 26(9): 897 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Criqui Obesity, Risk Factors, and Predicting Cardiovascular Events Circulation, April 19, 2005; 111(15): 1869 - 1870. [Full Text] [PDF]
|
|
|
|
|
|
R. Vettor, R. Serra, R. Fabris, C. Pagano, and G. Federspil Effect of Sibutramine on Weight Management and Metabolic Control in Type 2 Diabetes: A meta-analysis of clinical studies Diabetes Care, April 1, 2005; 28(4): 942 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Schuster Under-treated high-risk patients: identifying patients in high-risk subgroups and treating them to LDL-C targets Eur. Heart J. Suppl., March 1, 2005; 7(suppl_A): A20 - A28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Rizvi Metabolic Markers of Insulin Resistance in Overweight Persons Ann Intern Med, August 3, 2004; 141(3): 243 - 243. [Full Text] [PDF]
|
|
|
|
|
|
K. Pyorala, C. M. Ballantyne, B. Gumbiner, M. W. Lee, A. Shah, M. J. Davies, Y. B. Mitchel, T. R. Pedersen, and J. Kjekshus Reduction of Cardiovascular Events by Simvastatin in Nondiabetic Coronary Heart Disease Patients With and Without the Metabolic Syndrome: Subgroup analyses of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care, July 1, 2004; 27(7): 1735 - 1740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Aspects of Blood Pressure, Lipid, and Glycemic Treatment Diabetes Care, January 1, 2004; 27(1): 264 - 269. [Full Text] [PDF]
|
|
|
|
|
|
R. T. Hurst and R. W. Lee Increased Incidence of Coronary Atherosclerosis in Type 2 Diabetes Mellitus: Mechanisms and Management Ann Intern Med, November 18, 2003; 139(10): 824 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ellingsen, I. Hjermann, M. Abdelnoor, E. M Hjerkinn, and S. Tonstad Dietary and antismoking advice and ischemic heart disease mortality in men with normal or high fasting triacylglycerol concentrations: a 23-y follow-up study Am. J. Clinical Nutrition, November 1, 2003; 78(5): 935 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Haffner and H. Taegtmeyer Epidemic Obesity and the Metabolic Syndrome Circulation, September 30, 2003; 108(13): 1541 - 1545. [Full Text] [PDF]
|
|
|
|
|
|
N. Sattar, A. Gaw, O. Scherbakova, I. Ford, D. St.J. O'Reilly, S. M. Haffner, C. Isles, P. W. Macfarlane, C. J. Packard, S. M. Cobbe, et al. Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study Circulation, July 29, 2003; 108(4): 414 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.M. Ballantyne Raising high-density lipoprotein cholesterol: where are we now? Eur. Heart J. Suppl., June 1, 2003; 5(suppl_D): D17 - D25. [Abstract] [PDF]
|
|
|
|
|
|
S. Robins, C. M. Ballantyne, A. G. Olsson, T. J. Cook, M. F. Mercuri, T. R. Pedersen, and J. Kjekshus Low High-Density Lipoprotein Cholesterol and Response to Simvastatin Therapy in Scandinavian Simvastatin Survival Study (4S) * Response Circulation, July 9, 2002; 106 (2): e8 - e8. [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Nash Insulin Resistance, ADMA Levels, and Cardiovascular Disease JAMA, March 20, 2002; 287(11): 1451 - 1452. [Full Text] [PDF]
|
|